O ur understanding of cholestatic liver diseases has been profoundly advanced by the discovery of specific transport systems for bile acids (BAs) and dedicated (nuclear and G-protein-coupled) receptors for BA signaling.
(1-4) These new insights have allowed us to obtain a deeper understanding of impaired hepatobiliary excretory function resulting from hereditary and acquired transport defects and of the adaptive changes counteracting the liver injury caused by retained, potentially toxic, and proinflammatory biliary constituents, such as BAs, in cholestasis. (3, 5) Perhaps even more importantly, such novel insights now allow us to target impaired transport function, metabolism, and their regulatory networks therapeutically by restoring disrupted BA transport and signaling, thus ameliorating cholestatic liver injury. (3, 5) Given that BAs signal along their enterohepatic circulation, this article will review the new therapeutic opportunities that arise with interventions along their journey through the liver and intestine ( Fig. 1 ; Table 1 ). The focus of this article is on novel therapies beyond ursodeoxycholic acid (UDCA), the first available BA-based treatment for many cholestatic disorders. (6) The readers are referred to other excellent reviews more broadly covering other, for example, immune-targeted approaches to cholestatic disorders. (7, 8) 
Enterohepatic BA Circulation as Basis for Therapeutic Interventions
BAs undergo an enterohepatic circulation that depends on active transport systems in the liver and the intestine (Fig. 1) . (9) More specifically, BAs are excreted from hepatocytes into bile through the bile salt export pump (BSEP/ABCB11) at the bile canaliculus, reabsorbed in the ileum by the apical sodiumdependent bile salt transporter (ASBT/SLC10A2), and return to the liver through the portal blood feeding the liver sinusoids, where they are taken up by highly efficient basolateral transport systems (Na 1 -taurocholate cotransporting polypeptide [NTCP]/SLC10A1 for conjugated BAs, organic anion transporters [OATPs]/SLCO/SLC21 family for unconjugated BAs) into hepatocytes, thus limiting the amount of BA spillover into the systemic circulation, where other tissues outside the enterohepatic circulation, such as adipose tissue, muscle, adrenal glands, and kidney, get also exposed to BAs (Fig. 1) . BAs complete this enterohepatic circulation several times (approximately six to eight times) a day and are highly efficiently conserved within the enterohepatic circulation through 
Of note, it is only a weak ligand for FXR and TGR5, thus diluting the pool of endogenous ligands to these receptors. (2, 3) UDCA improved cholestatic liver injury in various animal models of intrahepatic cholestasis, (1, 4) but failed to improve cholestatic liver injury in the Mdr2
-/-mouse model of sclerosing cholangitis. (5) Used in treatment of several cholestatic liver disorders, prolongs survival without liver transplantation in PBC; beneficial effects in various cholestatic disorders (1, 6) FXR 
OCA: Improved cholestatic injury in various mouse models of cholestasis (estrogen, BDL), but not in Mdr2 -/-mice (8, 9) INT-767: Improved cholestatic injury in Mdr2
-/-mice (10) GW4064: Improved serum biochemistry and decreased inflammatory cell infiltration and bile duct proliferation in BDL-as well as in ANITinduced cholestasis (10) LJN452: Increases BSEP and SHP expression in primary human hepatocytes and improved liver transaminases and fibrosis in the ANIT model (11) PX20606 (12) and GS-9674 (13) improved hepatic fibrosis and portal hypertension in CCL 4 -and BDL-induced fibrosis as well as in a rat NASH model, respectively Steroidal FXR agonists: OCA: phase IIIa in PBC (POISE, NCT01473524) completed (14) and (10) TGR5 transgenic mice were protected against xenobioticinduced sclerosing cholangitis whereas mice lacking TGR5 showed aggravated injury. (15) BAR502: Amelioration of liver injury in ANIT and estrogeninduced cholestasis (16) Potential safety concerns attributed to possible role in pruritus, (17) gallbladder distension, (18, 19) and pro-proliferative and antiapoptotic effects in cholangiocytes and cholangiocellular cancer cell lines (20, 21) FGF19 mimetics NGM282/M70 FibApo Small-molecule ligands for FGF4R FGF19-mediated suppression of bile acid synthesis (classic and alternative pathways through CYP7A1 and sterol 27-hydrolase, respectively) Engineered FGF19 separates repression of BA synthesis from carcinogenic effects, competition with endogenous potentially carcinogenic FGF19 at FGF4R.
AAV-associated FGF19 overexpression improves cholestatic liver injury in Mdr2 -/-mouse model. (22) NGM 282/M70 inhibits BA synthesis and reduces hepatic BA accumulation in BDL and ANIT mice. (23) FibApo, a chimeric fusion protein composed of FGF19 and ApoA1, has potent hepatoprotective activities in the ANIT model. (24) NGM282: phase II in PBC completed (NCT02135536) (25) , ongoing phase IIb (NCT02026401) Phase II in PSC (NCT02704364) these active transport systems, thus limiting BA loss through feces to 3%-5% of daily secreted BAs, which need to be replenished by BA synthesis. (9) BAs that escape ileal reabsorption reach the colon, where they are deconjugated and metabolized (e.g., dehydroxylated) by gut microbiota to secondary BAs, which still can be passively absorbed as unconjugated BAs in the colon. (9) Unconjugated BAs are partially reconjugated 
GLP-1 exerts cholangioprotective effects in cholestasis (BDL). (27, 28) Recommended as first-line therapy for cholestatic pruritis, (29) (5, 37, 38) steatohepatitis in hepato-specific NEMO -/-mice, (39) hepatic inflammation and fibrosis in Schistosomainfected mice. (40) However, in Cftr -/-mice, norUDCA aggravated biliary injury. (41) Whereas tauro-norUDCA is ineffective in curing sclerosing cholangitis in Mdr2
-/-mice, (37) only tauro-norUDCA counteracts lithocholic-acidinduced cholestasis. (42) Phase II in PSC (NUC-3, NCT01755507), (43) phase III in planning
For (and rehydroxylated) during their passage through the liver before being excreted into bile again, (9) which completes their enterohepatic cycle.
BAs are also filtered by the glomeruli and then reabsorbed in renal tubules, again limiting their renal loss ( Fig. 1 ). Under cholestatic conditions, when induction of alternative basolateral transport systems facilitates the transport of BAs back from cholestatic hepatocytes into the blood, down-regulation of renal tubular transport systems further facilitates the elimination of BAs (and other biliary constituents, such as conjugated bilirubin) through urine. (3) In addition to their detergent function in lipid emulsification and absorption, BAs have important signaling properties in the liver and the intestine, which are mediated by nuclear hormone receptors such as the nuclear BA receptor, farnesoid X receptor (FXR: NR1H4), (10) (11) (12) and the membrane-bound BA receptor, TGR5 (also called GPBAR1 or M-BAR/BG37). (1, 13, 14) (Fig. 2 ). Besides FXR, BAs are able to activate other nuclear receptors (NRs), such as pregnane X receptor (PXR: NR1I2) and vitamin D receptor (NR1I1), (3, 5) as well as membrane a5b1 integrin, (15) epidermal growth factor receptor, (16) and sphingosine-1-phosphate receptor 2.
Ligand-activated NRs such as FXR control a broad range of metabolic processes, including hepatic BA transport and metabolism, lipid and glucose metabolism, drug disposition, as well as liver regeneration, inflammation, fibrosis, cell differentiation, and tumor formation. (2, 3, 5) Moreover, FXR has anti-inflammatory and immunomodulatory actions (18, 19) and controls intestinal integrity, permeability, as well as gut microbiota. (20, 21) Conversely, gut microbiota metabolize BAs (with formation of secondary BAs), which, in turn, modulates BA signaling (20) ( Fig. 2) . Based on these broad physiological effects in the liver and intestine, drugs targeting FXR and TGR5 therefore open important perspectives for pharmacotherapy of cholestatic and metabolic liver disorders, including the complications of liver cirrhosis, such as portal hypertension and hepatocellular carcinoma (HCC). (3, 5) During their passage along the enterohepatic circulation, BAs can signal as enterohepatic hormones through FXR, which is largely restricted to tissues/ organs of the enterohepatic circulation (liver, intestine), kidney, and adrenal glands, and through TGR5, which is more broadly expressed and more relevant for mediating systemic BA effects after their spillover into the systemic circulation (1, 2) (Fig. 2) . To put things into a rather simplified perspective, the liver could be viewed as an endocrine gland that secretes its steroid hormones (i.e., BAs) into bile, where they first exert their hormonal actions in the intestine, followed by signaling/hormonal effects in the enterohepatic and later systemic circulation after their (re)absorption. The direct hormonal actions of BAs through FXR and TGR5 are further amplified by induction of enterokines, such as fibroblast growth factor 19 (FGF19) (22) induced through FXR in the ileum and glucagon like peptide-1 (GLP-1; through TGR5) in the small intestine and colon (23) (Fig. 2) . FGF19 represses BA synthesis and lipogenesis, while promoting fatty acid oxidation and glycogen storage (22, 24) (Fig. 2) . GLP-1 has not only metabolic (e.g., insulin-sensitizing), but also potential hepatoprotective and cholangioprotective effects. (25) 
During their passage through the enterohepatic circulation, BAs have intensive mutual interactions with gut microbiota, which may be relevant in both health and disease (Fig. 2) . On the one hand, BAs control and modify microbiota through their detergent (directly bactericidal) and signaling (FXR and TGR5) properties and maintain intestinal integrity; on the other hand, BAs are metabolized by microbiota and can also serve as microbial nutrients. (20) Therefore, the exposure of microbiota to BAs has major consequences on bacterial composition and metabolic activity of gut microbiota, shaping their composition and enzymatic function. (20) Conversely, microbial BA metabolism may alter the signaling properties of BAs through FXR and TGR5 by changing their ligand affinities with subsequent broad metabolic consequences.
BA Receptor Ligand Drugs
FXR and TGR5 can now be targeted therapeutically by highly active and selective ligands. In addition, ligands with high affinity for both receptors are available (Table  1) . These pharmacological ligands have a much higher receptor affinity than endogenous BAs, thus allowing to separate their therapeutic signaling properties from other potentially harmful chemicals (e.g., detergent and proinflammatory) BA effects. Notably, genetic variants/mutations of FXR have recently been linked to the pathogenesis of hereditary and acquired cholestatic syndromes (26, 27) and inflammatory bowel disease. (28) The clinical lead compound is obeticholic acid (OCA), which is a 6-ethyl derivative of the primary BA, chenodeoxycholic acid, and a 100-fold more potent FXR ligand in in vitro reporter assays than its mother compound. (29) Like endogenous BAs, it undergoes an enterohepatic circulation and gut microbial metabolism. It has, however, to be considered that the signaling effects of (intestinal) metabolites of such BA-derived ligands may differ from their mother compound and could result in crossactivation of other receptors not primarily targeted by the mother compound. OCA improved cholestasis in primary biliary cholangitis (PBC) patients who were either na€ ıve or nonresponders to UDCA (30, 31) and also has shown promising (antisteatotic and -fibrotic) effects in NASH (32) and portal hypertension. (33) Adverse effects include pruritus and increases in low-density lipoprotein with reduction of high-density lipoprotein cholesterol. (30, 32) OCA was recently approved for treatment of PBC in patients not responding or intolerant to UDCA by the U.S. Food and Drug Administration (FDA). The therapeutic action of FXR ligands relies on potent anticholestatic and -inflammatory mechanisms, including repression of BA synthesis (cholesterol 7-alphahydroxylase; CYP7A1) (34) while, at the same time, stimulating the biliary secretion of BA (BSEP), (35) phospholipid (PL; via multidrug resistance protein 3 [MDR3]) (36) and bicarbonate (HCO 3 -), (37) as well as directly inhibiting proinflammatory transcriptions factors such as nuclear factor kappa B (NFjB). (19) These mechanisms reduce the exposure of the liver (and bile ducts) to toxic levels of BAs and attenuate their potentially harmful proinflammatory actions.
Of note, clinical studies also explore the beneficial mechanisms of fibrates (ligands for peroxisome proliferator-activated receptor alpha [PPARa]/NR1C1), which also repress BA synthesis, stimulate PL excretion, and have anti-inflammatory properties. (38) This therapeutic strategy may improve alkaline phosphatase (AP) levels in PBC patients not responding to UDCA (39) ; controlled clinical studies are underway (e.g., BEZURSO; NCT01654731). Other ligands for a/d (elafibranor) and PPARd (MBX-8025; NCT02609048) are also developed for clinically for cholestatic disorders, such as PBC.
Nonsteroidal FXR ligands may have different pharmacokinetic and therapeutic properties given that their transport and metabolism differ from endogenous BAs and BA-derived FXR ligands. Several of these compounds are tested in phase II clinical studies for the treatment of PBC and primary sclerosing cholangitis (PSC ; Table 1 ). Interestingly, some of the nonsteroidal FXR ligands (e.g., fexaramine) appear to operate as gut-selective, or at least gut-preferential, FXR ligands, a concept that has been proven beneficial in mouse models of nonalcoholic steatohepatitis (NASH). (40) Attributed to the key role of gut-derived FGF19 in repressing BA synthesis through CYP7A1, this concept may also hold some promise in treatment of cholestasis. Of note, intestinal overexpression of FXR stimulates production of Fgf15 (rodent homologue of human FGF19) and cures cholestasis in the Mdr2 -/-mouse model of sclerosing cholangitis. (41) Moreover, such gut-selective ligands could have a more direct effect on gut integrity and microbiota and might impact on inflammatory bowel disease and dysbiosis associated with cholestatic disorders, such as PSC. (42) TGR5 in liver-in contrast to FXR-is not expressed in hepatocytes, but cholangiocytes, gallbladder epithelium, as well as endothelial cells and Kupffer cells, where it mediates biliary HCO 3 -secretion and anti-inflammatory effects. (43, 44) This, together with TGR5 polymorphisms in PSC, (45) makes this receptor a promising therapeutic target in cholangiopathies. Additional advantages could include hepatoprotective effects from BA overload (46) and stimulation of intestinal GLP-1 with potential cholangioprotective mechanisms. (25) However, a pure TGR5 agonist did not improve cholestatic liver injury in the Mdr2 -/-mouse model of sclerosing cholangitis. (37) Additional concerns include the potential role of TGR5 in pruritus, (47) its high expression in gallbladder and gallbladder relaxation, (43, 48) potential pro-proliferative and antiapoptotic effects in isolated human cholangiocytes as well as cholangiocellular carcinoma cells, (49) and perhaps also its potent metabolic effects on energy expenditure (1) (which may be therapeutically desirable in NASH, but not in PBC). Collectively, these properties could explain why these compounds currently do not appear to be clinically suitable for cholestatic disorders.
FGF19 Mimetics
Given the key role of FGF19 (Fgf15 in rodents) in regulation of BA synthesis, (22) it appears reasonable to utilize this mechanism therapeutically. Pharmacological activation of FXR stimulates production of endogenous FGF19, which may, however, have unwanted, for example, pro-proliferative or even procarcinogenic effects (see below). Endogenous FGF19 and fibroblast growth factor receptor 4 (FGF4R) have been implicated in the development of HCC (and even some extrahepatic cancers), and inhibitors of FGF4R signaling have been proposed as anticancer treatment. (50) In humans, FGF19 is amplified in HCC, (51) and in mice, ectopic overexpression of FGF19 drives HCC development. (52) Notably, engineered FGF19 (M70, NGM282) with amino acid modifications in the Nterminus fully retains BA regulatory activity, but does not promote HCC formation, demonstrating that effects of FGF19 on BA metabolism can be separated from tumor-promoting activity. (53) Introducing an adeno-associated virus carrying the gene for the engineered FGF19 variant, M70, to Mdr2 -/-mice reversed liver injury, decreased hepatic inflammation, attenuated biliary fibrosis, and reduced cholecystolithiasis. (54) Mechanistically, M70 significantly inhibits classic and alternate BA synthetic pathways, thereby reducing BA levels. Importantly, prolonged exposure to FGF19, but not M70 (NGM282), led to the formation of HCC in Mdr2 -/-mice. (54) In addition to M70, several other FGF mimetics are available, which are, however, not yet explored for cholestasis. (55) Administration of M70 in healthy human volunteers potently reduced serum levels of 7a-hydroxy-4-cholesten-3-one (C4) as a surrogate marker for hepatic CYP7A1 activity (56) (Table 1) . However, it is important to keep in mind that-in contrast to rodents-FGF19 in humans appears to be produced also in hepatocytes and not only in the intestine. (57) Such species differences may be important for differential outcome/implications under cholestatic conditions with intrahepatic retention, but intestinal deficiency of FXR ligands. Patients with severe cholestasis (and liver cirrhosis) have very high endogenous FGF19 levels (58) and already maximal repression of endogenous BA synthesis and thus may not benefit from additional application of exogenous FGF19. Nevertheless, genetically modified FGF19 could still compete with endogenous FGF19 for potentially harmful (e.g., carcinogenic) effects at the FGF4R (Fig. 2) . It may therefore be reasonable to stratify the use of FGF19 (and other anticholestatic therapies) according to the levels of endogenous FGF19 and C4 as an indicator of BA synthesis.
Enterohepatic Circulation Blockers (Drugs Causing "Enteruption")
SURGICAL (PARTIAL) BILIARY DIVERSION, RESINS, ASBT BLOCKERS
Blocking intestinal BA absorption depletes the body from BA and-indirectly by promoting BA synthesis-also from cholesterol. BA binding resins are used
to treat pruritus and have also been reported to improve cholestasis on single occasions/in small series, although this has never been investigated systematically. (59) Equally, surgical procedures interrupting the enterohepatic circulation are effective not only to treat pruritus, but also to improve (hereditary) forms of cholestasis attributed to transporter defects, given that such partial external biliary diversion not only resolves hepatic morphologic abnormalities, but also increases the hydrophilicity of the BA pool. (60) Various resins are available for blocking the enterohepatic circulation (Table 1 ). Whereas colestyramine is poorly tolerated because of large doses and taste, the newer compounds can be formulated as pills or gels, which improves patients acceptance. However, a controlled clinical trial showed that BA sequestrants (e.g., colesevelam) are not sufficiently effective in treatment of cholestatic pruritus. (61) A range of highly selective, nonabsorbable blockers of ileal BA uptake through ASBT is also available ( Table 1) . Most of these drugs have primarily been designed to treat metabolic diseases and chronic constipation. Lopixibat (previously known as LUM001) and A4250 were shown to improve cholestatic liver injury and sclerosing cholangitis in Mdr2 -/-mice, which could be attributed to reduced biliary BA output with a beneficial BA/PL ratio despite stimulation of endogenous BA synthesis and suppression of FGF15 signaling. (62, 63) However, phase II clinical trials of Lopixibat plus UDCA for the management of PBC associated with itching and progressive familial intrahepatic cholestasis (PFIC) in pediatric patients have both been disappointing, although serum BA reductions and C4 increases suggested pharmacological activity (Table 1) . Additional interesting compounds include Elobixibat (another potent and selective ASBT inhibitor) and A3384 (a colonic release formulation of cholestyramine). GSK2330672 is another highly potent, nonabsorbable ASBT inhibitor, which is currently tested for treatment of pruritus in PBC ( Table 1) .
The therapeutic mechanisms of BA-binding resins and ASBT inhibitors may differ profoundly, although both reduce BA uptake and thereby hepatobiliary BA toxicity. Although BA bound to resins are no longer able to enter cells, they still can signal through TGR5. ASBT inhibitors allow free BAs to enter the colon, where they can signal through FXR. This may have important implications for secretion of GLP-1, which is stimulated by TGR5, (23) but suppressed by FXR (64) as well as for microbial BA metabolism.
NTCP BLOCKERS
Interference with NTCP may reduce hepatocellular BA uptake, subsequently altering biliary BA excretion and thereby hepatobiliary toxicity. Uptake of BAs appears to be a critical step for stimulating secretion of proinflammatory cytokines during cholestasis. (65) Although NTCP is down-regulated as an adaptive mechanism in cholestasis, (3) residual expression levels may still be accessible to therapeutic inhibition. Inhibition of NTCP can be achieved by Myrcludex B, which was designed as a peptide inhibitor of hepatitis B virus uptake, which requires docking to NTCP. (66) In addition to Myrcludex B, small-molecule inhibitors for NTCP are available. (67) Interestingly, genetic absence of NTCP in humans and mice results in hypercholanemia, but is otherwise well tolerated. (68, 69) 
INDIRECT CONSEQUENCES OF BSEP BLOCKADE
Whereas lack of BSEP causes severe and progressive cholestasis in humans, (70) Bsep -/-mice are protected from acquired cholestatic liver and bile duct injury as a result of metabolic preconditioning with formation of hydrophilic, less-toxic polyhydroxylated BAs. (71) This observation suggests that therapeutic administration of polyhydroxylated BAs or stimulation of enzymatic pathways involved in the formation of these BAs may be considered as a therapeutic strategy in cholestasis. Along this line, activators of constitutive androstane receptor and PXR-the NRs involved in BA detoxification (5) -might be of interest. Conversely, chaperones restoring defective BSEP function have been shown beneficial effects in patients with corresponding transporter mutations. (72) Under rare circumstances, direct blockade of BSEP could transiently protect bile ducts from BA-induced injury. This could be relevant, for example, in the posttransplant setting, where BSEP expression recovers more rapidly than MDR3, resulting in a less-favorable BA/PL ratio. (73) Inhibition of BSEP (e.g., by cyclosporine A), together with stimulation of MDR3 (fibrates, FXR ligands), could help to protect bile ducts during this stress period. However, it is important to emphasize that this hypothetical concept includes transient inhibition of BSEP only.
Cholehepatic Drugs
norUDCA is a side-chain-shortened derivative of UDCA and is resistant to side-chain conjugation (i.e., amidation with glycine and taurine). Therefore (and in contrast to UDCA undergoing full enterohepatic circulation between the intestine and the liver), nor-UDCA undergoes cholehepatic shunting between cholangiocytes and hepatocytes, which results in the generation of a HCO 3 2 -rich hypercholeresis. (74) Importantly, the process of cholehepatic shunting also results in high intrahepatic enrichment of the drug (presumably higher than with enterohepatic drugs) and could allow therapeutic targeting to the diseased bile duct system. To highlight these specific therapeutic properties, it appears appropriate to label this class of compounds as "cholehepatic drugs" ( Fig. 3 ; Table 1 ) in analogy to more traditional "'enterohepatic BA drugs," although perhaps better terms may be coined in the near future. Notably, norUDCA is not the only cholehepatic drug of its class; others include the nonsteroidal anti-inflammatory drug, sulindac, (75) which, however, performed rather disappointingly in clinical studies. (76) norUDCA has recently been successfully tested in a phase II clinical trial in PSC (Table 1) , based on promising results in preclinical mouse models of biliary injury and fibrosis. (77, 78) Notably, norUDCA is also less hydrophilic than UDCA, which, together with its different pharmacokinetic and pharmacodynamic profile, may make it more efficient than its parent compound. Given that norUDCA reinforces the HCO 3 -umbrella (independent from cystic fibrosis transmembrane conductance regulator [CFTR] and anion exchanger 2 [AE2]), (77) it may also hold some promise in other cholangiopathies with a defective HCO 3 -secretion/umbrella, such as PBC (linked to AE2 defects/variants) and cystic-fibrosis-related liver disease (CFTR defects). (79) Beside its beneficial effects on the biliary tree, norUDCA has also antiproliferative, but proregenerative, anti-inflammatory, and -fibrotic, thus direct hepatoprotective, properties (Table 1) . Importantly, the property of cholehepatic shunting may facilitate the combination with other (e.g., enterohepatic) drugs (or FGF-19 mimetics).
Conclusions and Outlook
Apparently, opposing (or even contradicting) strategies targeting the FXR-FGF19 axis may be beneficial in cholestatic liver and bile duct injury. As such, stimulation of FXR-FGF19 signaling with enterohepatic drugs (FXR ligands or FGF19 mimetics) may improve cholestasis (Fig. 3) . Conversely, inhibiting FXR-FGF19 signaling with enterohepatic blockers or cholehepatic drugs (diluting signaling) may be equally effective (Fig. 3) (85) ).
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antagonism in the field of metabolic liver diseases, (40, 80, 81) it will be interesting to see whether this also applies to cholestatic disorders. Notably, doubleknockout mice lacking both MDR2 and FXR show improved bile duct, but aggravated hepatic injury and inflammation. (82) Moreover, it may be important to distinguish the actions of intestinal versus hepatocellular or cholangiocellular FXR (or TGR5) signaling. Interestingly, UDCA may act as a weak indirect FXR antagonist by diluting the pool of more-potent endogenous FXR agonists. (83) Finally, studies in mice lacking FXR (84) or BSEP (71) have surprisingly revealed beneficial effects in cholestasis, which may be attributed to adaptive changes in BA transport and metabolism. Importantly, BAs may act as immunometabolic drugs, (18) which not only impact on cholestasis, but also modulate primary or secondary immunological and inflammatory (epi)phenomena in cholestasis.
Such immunomodulatory antiinflammatory actions may be important when targeting autoimmune/immune-mediated cholangiopathies and/or secondary immunological epiphenomena in cholangiopathies, such as PBC and PSC, and their overlap (variant) syndromes. (7, 8) After a long period of rather limited pharmacological options, a future challenge will be to clinically test the exploding number of therapeutic strategies and their potential combinations.
